The oncolytic adenovirus vaccine, DNX-2401, being developed by DNAtrix to treat recurrent glioblastoma, has received a fast-track status by the FDA.
DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma.
"We're very pleased to receive Fast Track status for DNX-2401 and are pleased that the FDA supports our position that there is an urgent need for additional therapies to treat glioblastoma," said Dr. Frank Tufaro, president and chief executive officer of DNAtrix. "Fast Track status reinforces our goal to quickly move forward with the development of DNX-2401. Recurrent glioblastoma is extremely challenging to treat, and clinical results from DNX-2401 to date indicate that the drug may be an important treatment option for the disease."
Press release: http://on.mktw.net/1nNoVCs
Source: MarketWatch
Female Adolescents With T1D Have Lower Quality of Life Than Male Children
January 27th 2023A systematic review evaluating sex differences in children with type 1 diabetes (T1D) found that female children had higher rates of comorbidities, higher body mass index, required higher insulin doses, and had a lower quality of life compared with male children.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
2 Clarke Drive
Cranbury, NJ 08512